Wu, Min http://orcid.org/0000-0001-9152-3402
Li, Cuiyun
Zhang, Hong
Sun, Jixuan
Zhu, Xiaoxue
Li, Xiaojiao
Gao, Xuedong
Wang, Wei
Ding, Yanhua
Funding for this research was provided by:
National Major Science and Technology Projects of China (2017ZX09304004, 2017ZX09101001-002-004)
National Natural Science Foundation of China (81602897)
Program for Jilin University Science and Technology Innovative Research Team (2017TD-08)
Article History
First Online: 22 July 2020
Compliance with Ethical Standards
:
: This project was financially sponsored by the following programs: National Major Scientific and Technological Special Project for Significant New Drug Development during the Thirteenth Five-Year Plan Period of China (Project: 2017ZX09304004, 2017ZX09101001-002-004), the National Natural Science Foundation of China (Project: 81602897), the program for JLU Science and Technology Innovative Research Team (2017TD-08), and the Fundamental Research Funds for the Central Universities.
: Min Wu, Cuiyun Li, Hong Zhang, Jixuan Sun, Xiaoxue Zhu, Xiaojiao Li, Xuedong Gao, Wei Wang, Yanhua Ding and Li Liu have no conflicts of interest that are directly relevant to the content of this article.
: The clinical study protocol was approved by the Ethics Committee at the Jilin University First Affiliated Hospital-Clinical Research Institute in Changchun City, Jilin Province, China. Clinical procedures were conducted in the Phase I Clinical Trial Unit of the First Hospital of Jilin University. The studies (Registration Nos.: CTR20170496 and CTR20180896,ExternalRef removed) were conducted in accordance with the Declaration of Helsinki and the Guidelines for Good Clinical Practice.
: Written informed consent was obtained from each participant before the study commenced.